Stock ANNX ANNEXON, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Annexon, Inc.

Equities

ANNX

US03589W1027

Market Closed - Nasdaq
Other stock markets
 01:00:00 2024-07-03 pm EDT 		5-day change 1st Jan Change
4.795 USD +5.04% Intraday chart for Annexon, Inc. -0.52% +5.62%
Jun. 25 Annexon Reports 'Positive' Results From Phase 3 Study of Guillain-Barre Syndrome MT
Jun. 25 Annexon Presented Additional Positive Phase 3 Results for ANX005 C1q-Targeted Immunotherapy in Guillain-Barré Syndrome at the 2024 PNS Annual Meeting CI

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
ANNEXON PRESENTED ADDITIONAL POSITIVE PHASE 3 RESULTS FOR ANX005 C1Q-TARGETED IMMUNOTHERAPY IN GUILLAIN-BARRE SYNDROME AT THE 2024 PNS ANNUAL MEETING
AQ
Annexon Reports 'Positive' Results From Phase 3 Study of Guillain-Barre Syndrome
MT
Annexon Presented Additional Positive Phase 3 Results for ANX005 C1q-Targeted Immunotherapy in Guillain-Barré Syndrome at the 2024 PNS Annual Meeting
GL
Annexon Presented Additional Positive Phase 3 Results for ANX005 C1q-Targeted Immunotherapy in Guillain-Barré Syndrome at the 2024 PNS Annual Meeting
CI
ANNEXON TO PRESENT PIVOTAL PHASE 3 DATA ON EARLY AND DURABLE BENEFITS WITH FIRST-IN-CLASS C1Q BLOCKING ANTIBODY ANX005 IN GUILLAIN-BARRE SYNDROME AT 2024 PNS ANNUAL MEETING
AQ
ANNEXON REPORTS INDUCEMENT GRANTS TO NEW EMPLOYEES UNDER NASDAQ LISTING RULE 5635(4)
AQ
Annexon To Present Pivotal Phase 3 Data On Early And Durable Benefits With First-In-Class C1q Blocking Antibody ANX005 In Guillain-Barré Syndrome At 2024 PNS Annual Meeting
GL
Annexon To Present Pivotal Phase 3 Data On Early And Durable Benefits With First-In-Class C1q Blocking Antibody ANX005 In Guillain-Barré Syndrome At 2024 PNS Annual Meeting
AQ
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
GL
Annexon : Topline Results from Phase 3 Study of ANX005 in Guillain-Barré Syndrome
PU
Sector Update: Health Care Stocks Steady Premarket Thursday
MT
Annexon Prices $125 Million Stock Offering
MT
Annexon Announces Pricing of $125 Million Underwritten Public Offering
GL
Sector Update: Health Care Stocks Steady Premarket Wednesday
MT
ANNEXON ANNOUNCES POSITIVE TOPLINE RESULTS FROM PIVOTAL PHASE 3 TRIAL FOR FIRST-IN-CLASS C1Q BLOCKING ANTIBODY ANX005 IN GUILLAIN-BARRE SYNDROME
AQ
Annexon Launches $125 Million Share Offering
MT
Annexon Announces Proposed Public Offering of Common Stock
GL
Sector Update: Health Care Stocks Steady Pre-Bell Tuesday
MT
Traders on Edge Amid Signs of Weaker Economic Growth, Stifling US Equity Futures Pre-Bell
MT
Sector Update: Health Care
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ANNX Stock
  4. News Annexon, Inc.